To the best of our knowledge, our study provided new insights regarding the interaction between serum myeloperoxidase levels, endothelial dysfunction parameters (L-arginine, ADMA, SDMA) and ROS, and the impact of this interaction on clinical features including the microvascular obstruction infarct size and ventricular remodeling. The gene discussed is MPO; the disease is endothelial dysfunction.